Voyager Therapeutics, Inc. (VYGR) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Current obligations | 16.68M USD | Liabilities, Current |
| Cash and equivalents | 35.77M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 80.57M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $16.68M | $35.77M | $80.57M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $17.45M | $43.31M | $98.17M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $26.54M | $65.30M | $131.15M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $35.49M | $45.13M | $163.81M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $41.98M | $43.94M | $171.65M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $40.21M | $74.75M | $161.26M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $49.79M | $71.37M | $195.32M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $44.21M | $112.53M | $232.84M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $40.13M | $76.13M | $294.89M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $72.55M | $143.08M | $256.49M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $64.51M | $68.80M | $162.07M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $61.69M | $65.27M | $187.67M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $45.40M | $244.29M | $28.45M | (m) | (m) | (m) |
| 2023-03-31 | (m) | $19.94M | $268.32M | $4.99M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $72.59M | $98.96M | $19.89M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $73.24M | $96.86M | $34.78M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $97.93M | $78.33M | $69.73M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $101.68M | $131.87M | $34.96M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $50.98M | $117.43M | $15.11M | (m) | (m) | (m) |
| 2021-09-30 | (m) | $26.70M | $111.47M | $10.02M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $24.69M | $117.84M | $25.14M | (m) | (m) | (m) |
| 2021-03-31 | (m) | $24.75M | $117.80M | $43.71M | (m) | (m) | (m) |
| 2020-12-31 | (m) | $26.77M | $104.44M | $76.70M | (m) | (m) | (m) |
| 2020-09-30 | (m) | $42.05M | $147.45M | $52.57M | (m) | (m) | (m) |
| 2020-06-30 | (m) | $67.53M | $144.32M | $85.35M | (m) | (m) | (m) |
| 2020-03-31 | (m) | $72.54M | $165.23M | $85.70M | (m) | (m) | (m) |
| 2019-12-31 | (m) | $76.01M | $86.04M | $195.49M | (m) | (m) | (m) |
| 2019-09-30 | (m) | $80.17M | $82.64M | $224.76M | (m) | (m) | (m) |
| 2019-06-30 | (m) | $69.15M | $79.89M | $247.58M | (m) | (m) | (m) |
| 2019-03-31 | (m) | $58.78M | $113.26M | $245.24M | (m) | (m) | (m) |
| 2018-12-31 | (m) | $31.67M | $46.86M | $108.95M | (m) | (m) | (m) |
| 2018-09-30 | (m) | $30.03M | $42.14M | $137.46M | (m) | (m) | (m) |
| 2018-06-30 | (m) | $29.09M | $59.61M | $136.51M | (m) | (m) | (m) |
| 2018-03-31 | (m) | $30.94M | $140.37M | $77.83M | (m) | (m) | (m) |
| 2017-12-31 | (m) | $15.90M | $31.53M | $137.52M | (m) | (m) | (m) |
| 2017-09-30 | (m) | $20.94M | $48.20M | $77.39M | (m) | (m) | (m) |
| 2017-06-30 | (m) | $11.84M | $66.30M | $75.02M | (m) | (m) | (m) |
| 2017-03-31 | (m) | $11.06M | $43.60M | $114.07M | (m) | (m) | (m) |
| 2016-12-31 | (m) | $13.80M | $36.64M | $137.78M | (m) | (m) | (m) |
| 2016-09-30 | (m) | $19.39M | $63.51M | $127.65M | (m) | (m) | (m) |
| 2016-06-30 | (m) | $19.76M | $67.03M | $136.96M | (m) | (m) | (m) |
| 2016-03-31 | (m) | $23.08M | $33.90M | $170.10M | (m) | (m) | (m) |
| 2015-12-31 | (m) | $23.93M | $31.31M | $163.03M | (m) | (m) | (m) |
| 2015-09-30 | (m) | $23.37M | $66.53M | $41.14M | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | $84.75M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | $116.41M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $2.47M | $7.04M | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | $6.33M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | $135.00K | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |